Clinical Trial Update: Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria

View source ↗

Summary

The document indicates that the expanded access protocol for givosiran in acute hepatic porphyria has been approved for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Porphyria

Drugs mentioned

• GIVLAARI (Givosiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Acute Hepatic Porphyria | Status: APPROVED_FOR_MARKETING